NCT07044232 NICardipine for Fast Achievement of Systolic BP Targets in ICH
| NCT ID | NCT07044232 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Aarhus University Hospital |
| Condition | Intracerebral Haemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 88 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 88 participants in total. It began in 2025-10-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Quality improvement study with a quasi-randomized design. The study monitors the effect of a gradually implemented treatment algorithm prioritizing intravenous antihypertensives (e.g., nicardipine) over long-acting nitrate patches. It aims to increase the proportion of patients reaching target systolic BP \<140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and healthcare resource utilization.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Acute spontaneous Intracerberal Hemorrhage confirmed by imaging * Symptom onset to stroke center admission \<6 hours * Elevated systolic blood pressure (\>140 mmHg) at admission Exclusion Criteria: * Secondary causes of ICH (e.g., trauma, vascular malformation) * Presumed fatal bleeding at admission * Short remaining life expectancy (\<12 month)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07044232 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intracerebral Haemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07044232 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07044232 currently recruiting?
Yes, NCT07044232 is actively recruiting participants. Contact the research team at rolfblau@rm.dk for enrollment information.
Where is the NCT07044232 trial being conducted?
This trial is being conducted at Aarhus, Denmark.
Who is sponsoring the NCT07044232 clinical trial?
NCT07044232 is sponsored by Aarhus University Hospital. The trial plans to enroll 88 participants.